



It Starts With You!

Join the research effort for
ENDOGENOUS CUSHING'S SYNDROME.

Consider the LOGICS study.

The logo for the LOGICS study. The word "LOGICS" is written in a bold, white, sans-serif font. The letter "I" is replaced by a stylized yellow human figure with its arms raised in a 'V' shape, symbolizing a person or a volunteer. The figure is positioned between the "G" and the "C".

LOGICS

Now seeking volunteers to participate in a
clinical study for an investigational drug,
levoketoconazole (COR-003).

Talk to your study doctor to learn more about
the LOGICS study. You can also go to
www.CushingsTrial.com
for more information

WHAT IS ENDOGENOUS CUSHING'S SYNDROME

Endogenous Cushing's syndrome occurs when the body produces too much cortisol. Most forms of endogenous Cushing's syndrome are caused by tumors in the pituitary gland, and others by tumors in the adrenal glands, or in other places throughout the body (ectopic tumors).

WHAT IS THE PURPOSE OF THE STUDY?

The purpose of this study is to compare the effects and safety of levoketoconazole (COR-003) compared to a placebo (a pill with inactive ingredients) on people with endogenous Cushing's syndrome. The safety and efficacy of levoketoconazole for treatment of endogenous Cushing's syndrome have not been established.

WHAT DOES THE STUDY INVOLVE?

This study includes three parts. In part one, eligible participants who are not currently taking levoketoconazole (group 1) will start taking levoketoconazole. Your study doctor will increase the dose slowly and see how well you respond. This part of the study is open-label. This means that both you and your study doctor are aware of the treatment being given. If you are currently taking levoketoconazole (group 2), then you will not participate in this part of the study.

In part two of the study, all participants will be assigned to a study group by chance (like a coin flip) rather than by a medical decision made by the researchers. During this part of the study, there is a 50% chance that you will continue taking levoketoconazole and a 50% chance that you will receive a placebo. Neither you nor your study doctor will know what you will receive.

In the third part of the study, both groups will receive levoketoconazole and placebo at the same time. If you were receiving placebo during the second part of the study, you would start taking levoketoconazole again in addition to the placebo. If you were receiving levoketoconazole during the second part of the study, you would also start taking placebo.

Levoketoconazole and placebo will be taken by mouth in tablet form.

Throughout the study, participants can expect to meet regularly with a study doctor and take part in a variety of medical tests. The study doctor will test how well the medication is working— and make adjustments if necessary— primarily by measuring the cortisol levels in urine and secondarily by recording changes over time in other measures of health that include a variety of tests using samples of blood, saliva and urine, physical examinations and responses to questions about your health.

Because this study is also being done to learn more about possible side effects, participants will need to let the study doctor know about changes in their usual health.

Your study doctor will carefully monitor your condition and, if your conditions worsens, may change the dose of study medication or withdraw you from the study.

WHO IS ELIGIBLE?

The study is for adults (18 years or older) with a diagnosis of endogenous Cushing's syndrome confirmed by your doctor. A study doctor can talk to you about whether or not you are eligible. If you would like to be considered for the study, please talk to your doctor or visit www.CushingsTrial.com and fill out the form.

ABOUT STRONGBRIDGE BIOPHARMA

Strongbridge Biopharma is a global, commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Cortendo AB is a Strongbridge Biopharma company and the sponsor of the LOGICS study. This means Cortendo planned and organized this study, and will also collect and analyze the data from the study.



www.CushingsTrial.com

www.strongbridgebio.com

Copyright ©2017 Strongbridge Biopharma plc

Cortendo AB is a Strongbridge Biopharma company and
the sponsor of the COR-003 LOGICS study.